Santen Pharmaceutical said on September 1 that it has released its glaucoma and ocular hypertension treatment Tapcom (tafluprost + timolol) in China through its local subsidiary.The drug is a preservative-free combination eye drop for lowering the intraocular pressure in patients…
To read the full story
Related Article
- Santen’s Glaucoma Drug Tapcom Snags China Approval
April 7, 2025
- Santen’s Glaucoma Med Tapcom Accepted for Review in China
February 9, 2023
BUSINESS
- AstraZeneca Japan Chief Says MFN Response Requires Drug Pricing Reform
August 5, 2026
- AstraZeneca Sees Broad Pipeline, AI Powering 50-Plus Approval Goal
August 5, 2026
- Voyxact PIII Data Confirm Kidney Function Stabilization in IgAN
August 5, 2026
- Perioperative Imfinzi Seen Advancing Gastric Cancer Care: Oncologist
August 5, 2026
- Teijin Still Seeking “Best Owner” for Legacy Drug Portfolio
August 5, 2026
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…





